Asthma Pharmacogenomics: 2015 Update

Current Allergy and Asthma Reports

Volumn 15, Issue 7, 2015, Pages

  Davis, Joshua S ^a,b   Weiss, Scott T ^a,c   Tantisira, Kelan G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c LABORATORY FOR MOLECULAR MEDICINE   (United States)

Author keywords

Asthma; Genes; GWAS; Pharmacogenetics; Pharmacogenomics; Systems biology

Indexed keywords

ARACHIDONIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLUCOCORTICOID; LEUKOTRIENE DERIVATIVE; MONTELUKAST; SALMETEROL; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

AIRWAY OBSTRUCTION; ASTHMA; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EPIGENETICS; GENE EXPRESSION REGULATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MEDICAL RESEARCH; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; QUANTITATIVE TRAIT LOCUS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; IMMUNOLOGY; PROCEDURES;

ASTHMA; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; PHARMACOGENETICS;

EID: 84937403954     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-015-0544-y     Document Type: Review

References (101)

1. To T et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.
2. Fanta CH. Asthma. N Engl J Med. 2009;360(10):1002–14.
3. Bahadori K et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.
4. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma—summary report. J Allergy Clin Immunol. 2007;120(5 Suppl):S94–S138.
5. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–25. Review focusing on heterogeneity of asthma and characterization of phenotypes. Important concept in asthma pharmacogenomics given such phenotyping will lead to personalized approaches to therapy.
6. Kalimp W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8(4):283–9.
7. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2000;56(4):1054–70.
8. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107–19.
9. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet. 2006;7:223–45.
10. United States. Department of Health and Human Services et al. Guidance for industry: E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. In: Guidance for industry ICH-E15. Rockville: Center for Drug Evaluation and Research; 2008.
11. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144–53.
12. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63(2):437–59.
13. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol. 2006;117(1):18–24. quiz 25.
14. Lehmann S et al. Bronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a beta2-agonist. Pulm Pharmacol Ther. 2006;19(4):272–80.
15. Ortega VE. Pharmacogenetics of beta2 adrenergic receptor agonists in asthma management. Clin Genet. 2014;86(1):12–20. Recent pharmacogenetics review of β2-agonist pathway.
16. Hawkins GA et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med. 2006;174(10):1101–9.
17. Chung LP, Waterer G, Thompson PJ. Pharmacogenetics of beta2 adrenergic receptor gene polymorphisms, long-acting beta-agonists and asthma. Clin Exp Allergy. 2011;41(3):312–26.
18. Green SA et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 1995;13(1):25–33.
19. Taylor DR et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000;55(9):762–7.
20. Israel E et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162(1):75–80.
21. Israel E et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364(9444):1505–12. Landmark BARGE trial, which was the first genotype-stratified asthma pharmacogenomic trial.
22. Bleecker ER et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol. 2006;118(4):809–16.
23. Bleecker ER et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007;370(9605):2118–25.
24. Bleecker ER et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med. 2010;181(7):676–87.
25. Wechsler ME et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009;374(9703):1754–64.
26. Lipworth BJ et al. Tailored second-line therapy in asthmatic children with the Arg(16) genotype. Clin Sci (Lond). 2013;124(8):521–8.
27. Zuurhout MJ et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the PACMAN cohort. Pharmacogenomics. 2013;14(16):1965–71.
28. Ortega VE et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting beta agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir Med. 2014;2(3):204–13.
29. Tantisira KG et al. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet. 2005;14(12):1671–7.
30. Kim SH et al. Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy. J Clin Pharm Ther. 2011;36(3):399–405.
31. Litonjua AA et al. ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med. 2008;178(7):688–94.
32. Duan QL et al. A polymorphism in the thyroid hormone receptor gene is associated with bronchodilator response in asthmatics. Pharmacogenomics J. 2013;13(2):130–6.
33. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet. 2010;11(4):241–6.
34. Himes BE et al. Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene. PLoS Genet. 2012;8(7):e1002824. One of the first major GWAS for β2-agonists pathway consisting of large cohort examining BDR that found SPATS2L gene variant with subsequent functional study identifying possible mechanism related to regulation of β2-AR.
35. Israel E et al. Genome-wide association study of short-acting beta2-agonists: a novel genome wide significant locus on chromosome 2 near ASB3. Am J Respir Crit Care Med. 2015;191:530–7.
36. Duan QL et al. A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics J. 2014;14(1):41–7.
37. Padhukasahasram B et al. Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups. Pharmacogenomics J. 2014;14(4):365–71.
38. Himes BE et al. Predicting response to short-acting bronchodilator medication using Bayesian networks. Pharmacogenomics. 2009;10(9):1393–412.
39. Drake KA et al. A genome-wide association study of bronchodilator response in Latinos implicates rare variants. J Allergy Clin Immunol. 2014;133(2):370–8. Example of GWAS of BDR in Latino children that utilized mixture mapping and detected multiple variants including two rare variants.
40. Robinson D et al. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression. Am Rev Respir Dis. 1993;148(2):401–6.
41. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther. 2002;15(1):35–50.
42. Cooper PR, Panettieri Jr RA. Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways. J Allergy Clin Immunol. 2008;122(4):734–40.
43. Jin SL et al. Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol. 2010;126(6):1252–1259 e12.
44. Nino G et al. Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta2-adrenoceptor agonist exposure. J Allergy Clin Immunol. 2010;125(5):1020–7.
45. Szefler SJ et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109(3):410–8.
46. Inglis GC et al. Familial pattern of corticosteroids and their metabolism in adult human subjects—the Scottish Adult Twin Study. J Clin Endocrinol Metab. 1999;84(11):4132–7.
47. Tantisira KG et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004;13(13):1353–9. Important candidate gene approach in corticosteroid pathway that identified two variations in CRHR1 in response to ICS therapy.
48. Tantisira KG et al. Chromosome 17: association of a large inversion polymorphism with corticosteroid response in asthma. Pharmacogenet Genomics. 2008;18(8):733–7.
49. Mougey EB et al. Pharmacogenetics of asthma controller treatment. Pharmacogenomics J. 2013;13(3):242–50.
50. Hawkins GA et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J Allergy Clin Immunol. 2009;123(6):1376–1383 e7.
51. Ye YM et al. Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control with inhaled corticosteroid treatment. J Clin Pharm Ther. 2009;34(6):693–701.
52. Kim MH et al. A polymorphism in the histone deacetylase 1 gene is associated with the response to corticosteroids in asthmatics. Korean J Intern Med. 2013;28(6):708–14.
53. Wu AC et al. Inhaled corticosteroid treatment modulates ZNF432 gene variant’s effect on bronchodilator response in asthmatics. J Allergy Clin Immunol. 2014;133(3):723–728 e3.
54. Stockmann C et al. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control. J Pediatr. 2013;162(6):1222–1227e1.
55. Tantisira KG et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med. 2011;365(13):1173–83. Major GWAS study in corticosteroid pathway identifying variant in GLCCl1 in response to ICS.
56. Hosking L et al. GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma. J Allergy Clin Immunol. 2014;133(2):587–9.
57. Vijverberg SJ et al. Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. Pharmacogenomics. 2014;15(6):799–806.
58. Tantisira KG et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med. 2012;185(12):1286–91.
59. Park HW et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J Allergy Clin Immunol. 2014;133(3):664–669 e5.
60. Perin P, Potocnik U. Polymorphisms in recent GWA identified asthma genes CA10, SGK493, and CTNNA3 are associated with disease severity and treatment response in childhood asthma. Immunogenetics. 2014;66(3):143–51.
61. Wang Y, et al. Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma. Pharmacogenomics J. 2015.
62. Wu R et al. A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics. Drug Discov Today. 2011;16(19–20):884–90. Review article about pharmacodynamic principles of drug response describing techniques incorporated into subsequent GWAS studies.
63. Himes BE et al. RNA-Seq transcriptome profiling identifies CRISPLD2 as a glucocorticoid responsive gene that modulates cytokine function in airway smooth muscle cells. PLoS One. 2014;9(6):e99625.
64. Qiu W et al. Pharmacogenomics: novel loci identification via integrating gene differential analysis and eQTL analysis. Hum Mol Genet. 2014;23(18):5017–24. First qQTL study related to asthma pharmacogenomics that resulted in discovery of multiple novel loci in the corticosteroid pathway.
65. Ritchie MD et al. Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genet. 2015;16(2):85–97.
66. Grundberg E et al. Global analysis of the impact of environmental perturbation on cis-regulation of gene expression. PLoS Genet. 2011;7(1):e1001279.
67. Tantisira KG, Drazen JM. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol. 2009;124(3):422–7.
68. Scadding GW, Scadding GK. Recent advances in antileukotriene therapy. Curr Opin Allergy Clin Immunol. 2010;10(4):370–6.
69. Sampson AP et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax. 2000;55 Suppl 2:S28–31.
70. Asano K et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics. 2002;12(7):565–70.
71. Lima JJ et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006;173(4):379–85.
72. Klotsman M et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics. 2007;17(3):189–96.
73. Telleria JJ et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med. 2008;102(6):857–61.
74. Kang MJ et al. Polymorphisms of the PTGDR and LTC4S influence responsiveness to leukotriene receptor antagonists in Korean children with asthma. J Hum Genet. 2011;56(4):284–9.
75. Mougey EB et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009;19(2):129–38.
76. Dahlin A, et al. Pharmacogenomics: novel loci identification via integrating gene differential analysis and eQTL analysis. Pharmacogenomics J. 2015. In press.
77. McCallister JW. Reslizumab and eosinophilic asthma: one step closer to phenotype-directed therapy? Am J Respir Crit Care Med. 2011;184(10):1096–7.
78. Sittka A et al. Asthma phenotyping, therapy, and prevention: what can we learn from systems biology? Pediatr Res. 2013;73(4 Pt 2):543–52.
79. Vijverberg SJ et al. Clinical utility of asthma biomarkers: from bench to bedside. Biologics. 2013;7:199–210.
80. Corren J et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–98.
81. Comer BS et al. Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther. 2015;147C:91–110.
82. Gunawardhana LP et al. Characteristic DNA methylation profiles in peripheral blood monocytes are associated with inflammatory phenotypes of asthma. Epigenetics. 2014;9(9):1302–16.
83. Rastogi D, Suzuki M, Greally JM. Differential epigenome-wide DNA methylation patterns in childhood obesity-associated asthma. Sci Rep. 2013;3:2164.
84. Seumois G et al. Epigenomic analysis of primary human T cells reveals enhancers associated with TH2 memory cell differentiation and asthma susceptibility. Nat Immunol. 2014;15(8):777–88.
85. Gaffin JM et al. Beta-2 adrenergic receptor gene methylation is associated with decreased asthma severity in inner-city schoolchildren: asthma and rhinitis. Clin Exp Allergy. 2014;44(5):681–9.
86. Sessa R, Hata A. Role of microRNAs in lung development and pulmonary diseases. Pulm Circ. 2013;3(2):315–28.
87. Booton R, Lindsay MA. Emerging role of MicroRNAs and long noncoding RNAs in respiratory disease. Chest. 2014;146(1):193–204.
88. Perry MM et al. Role of non-coding RNAs in maintaining primary airway smooth muscle cells. Respir Res. 2014;15:58.
89. Collison A et al. Altered expression of microRNA in the airway wall in chronic asthma: miR-126 as a potential therapeutic target. BMC Pulm Med. 2011;11:29.
90. Solberg OD et al. Airway epithelial miRNA expression is altered in asthma. Am J Respir Crit Care Med. 2012;186(10):965–74.
91. Bunyavanich S, Schadt EE. Systems biology of asthma and allergic diseases: a multiscale approach. J Allergy Clin Immunol. 2015;135(1):31–42.
92. Teran LM, et al. Respiratory proteomics: from descriptive studies to personalized medicine. J Proteome Res. 2014.
93. Terracciano R et al. Asthma and COPD proteomics: current approaches and future directions. Proteomics Clin Appl. 2015;9(1–2):203–20.
94. Nobakht MGBF et al. The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. Biomarkers. 2015;20(1):5–16.
95. Sharma A et al. A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes. Hum Mol Genet. 2015;24:3005–20. One of first studies in asthma pharmacogenomics that utilized an integrative or multiple “omics” approach leading to discovery of novel modulator in corticosteroid pathway.
96. Kittanakom S et al. CHIP-MYTH: a novel interactive proteomics method for the assessment of agonist-dependent interactions of the human beta(2)-adrenergic receptor. Biochem Biophys Res Commun. 2014;445(4):746–56.
97. McCarty CA, Wilke RA. Biobanking and pharmacogenomics. Pharmacogenomics. 2010;11(5):637–41.
98. Chen R et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148(6):1293–307.
99. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464–7.
100. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–5.
101. Kittanakom S et al. CHIP-MYTH: a novel interactive proteomics method for the assessment of agonist-dependent interactions of the human β2-adrenergic receptor. Biochem Biophys Res Commun. 2014;445(4):746–56.